🦠 microbiology

Archaic translation initiation factor eIF5B supports KSHV late lytic replication and viral oncogenesis by mimicking a hypoxic cellular landscape

This study reveals that Kaposi's Sarcoma-associated Herpesvirus (KSHV) hijacks the archaic translation initiation factor eIF5B to bypass eIF2-mediated translational shutdown during infection, thereby mimicking a hypoxic cellular environment to drive viral replication, oncogenic transformation, and angiogenesis.

Original authors: shembade, n., McDonald, C., Omayra Mendez-SolIs, O., Tan, Y.-D., Naipauer, J., Khasa, R., Ahuja, A., Karaca, E., Marcelo, Y., Ruiz-Ocana, N., Noussi, C. D., Tran, T. M. D., Hare, J. M., Roy, S., Lee

Published 2026-02-26

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: shembade, n., McDonald, C., Omayra Mendez-SolIs, O., Tan, Y.-D., Naipauer, J., Khasa, R., Ahuja, A., Karaca, E., Marcelo, Y., Ruiz-Ocana, N., Noussi, C. D., Tran, T. M. D., Hare, J. M., Roy, S., Lee, S., Mesri, E.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

The Big Picture: A Viral Heist in a "Low-Oxygen" World

Imagine your body is a bustling city. Inside the cells of this city, there is a massive factory that builds proteins (the bricks and mortar of life). To keep the factory running, the city needs a specific set of tools and managers, including a key manager called eIF2.

Now, imagine a sneaky burglar: the KSHV virus (the virus that causes Kaposi's Sarcoma, a type of cancer). This burglar wants to hijack the factory to build its own products (new viruses) instead of the city's products.

Usually, when a cell senses stress (like a lack of oxygen), it shuts down the main factory manager (eIF2) to save energy. In a normal "low-oxygen" emergency, the city has a backup plan: it uses an ancient, rarely used tool called eIF5B to keep a few critical machines running.

The Discovery: This paper reveals that the KSHV virus is a master manipulator. Even when there is plenty of oxygen (a normal, healthy city), the virus tricks the cell into thinking it's in a low-oxygen emergency. It shuts down the main manager (eIF2) and forces the cell to use the ancient backup tool (eIF5B). The virus then uses this backup tool to build its own late-stage products, allowing it to multiply and eventually turn the cell into a cancerous tumor.

The Story in Three Acts

Act 1: The Fake Emergency

Normally, cells only use the ancient backup tool (eIF5B) when they are starving for oxygen. It's like using a hand-crank flashlight only when the power grid goes down.

However, the KSHV virus is clever. It creates a "fake emergency." It tells the cell's security system to lock the main manager (eIF2) out of the factory. Suddenly, the factory stops making normal city goods. But the virus doesn't care; it needs to keep working.

Act 2: The Ancient Tool Takes Over

Because the main manager is locked out, the cell panics and grabs the ancient backup tool, eIF5B.

The Analogy: Think of eIF5B as a "dinosaur-era" tool. It's been sitting in the basement for billions of years, waiting for a real emergency.
The Twist: The virus hijacks this dinosaur tool. It forces the cell to use this ancient machinery to build viral products instead of cell products.
The Result: The virus uses this tool to build its "late-stage" products (the final parts of the virus needed to infect other cells). Without this ancient tool, the virus's assembly line stops, and it can't spread.

Act 3: The Cancer Connection

Why does this matter for cancer?
When the cell uses this ancient, low-oxygen tool, it starts acting like a cell that is starving for oxygen. This triggers a chain reaction:

Angiogenesis: The cell starts building new blood vessels (like a city building new roads to bring in supplies). This is great for a tumor because tumors need blood to grow.
Transformation: The cell starts behaving aggressively, ignoring the rules that keep it in place. It starts growing uncontrollably, leading to cancer.

The paper shows that if you remove this ancient tool (eIF5B) from the virus's toolkit, the virus can't finish building its products, the fake emergency stops, and the cancerous growth slows down significantly.

Key Takeaways (The "So What?")

The Virus is a Trickster: KSHV doesn't just break into the cell; it reprograms the cell's internal logic. It makes a healthy cell act like a dying, oxygen-starved cell.
The "Dinosaur" Tool is Vital: The ancient factor eIF5B is usually unimportant in healthy cells. But for this virus, it is the most important tool in its arsenal. It's the "secret weapon" the virus needs to finish its job.
A New Target for Medicine: Because healthy cells don't really need this ancient tool when there is plenty of oxygen, but the virus desperately needs it, scientists have found a new target.
- The Metaphor: If you want to stop a burglar who is using a specific, rare key to pick a lock, you don't need to lock every door in the city. You just need to jam that one specific key.
- The Hope: Drugs that block eIF5B could stop the virus from replicating and stop the cancer from growing, without hurting the healthy cells that don't rely on this tool.

Summary

This paper tells the story of how a virus tricks a cell into using an ancient, emergency-only tool to build a cancerous empire. By understanding this trick, scientists have found a new way to potentially stop the virus and the cancer it causes.

1. Problem Statement

Kaposi's Sarcoma-associated Herpesvirus (KSHV) is the etiological agent of Kaposi's Sarcoma (KS) and Primary Effusion Lymphoma. A critical challenge in viral oncology is understanding how KSHV sustains protein synthesis and replication when host cells attempt to shut down global translation as an antiviral defense mechanism (often triggered by stress or hypoxia).

While it is known that KSHV manipulates the hypoxia-inducible factor (HIF) pathway to create a "hypoxia-like" environment even under normoxic conditions, the specific molecular mechanisms allowing the virus to bypass canonical translation inhibition (specifically the phosphorylation of eIF2 $\alpha$ ) remain poorly understood. The study seeks to identify the alternative translation initiation machinery KSHV recruits to ensure the synthesis of late lytic viral genes and drive oncogenesis.

2. Methodology

The researchers employed a multi-faceted approach combining cell biology, molecular genetics, and bioinformatics:

Cell Models:
- iSLK.219 Cells: A doxycycline (DOX)-inducible human cell line harboring recombinant KSHV (rKSHV219), allowing controlled induction of the lytic cycle.
- Primary hMSCs: Human Mesenchymal Stem Cells used for de novo infection to model natural infection and KS-like transformation.
- mMSC.219: Mouse MSCs infected with rKSHV219 for soft-agar colony formation assays.
Genetic Manipulation:
- Knockdown: siRNA-mediated silencing of eIF5B and eIF2D (a potential alternative factor) to assess functional necessity.
- Knockout: shRNA-mediated stable knockout of eIF5B in mouse MSCs.
Molecular Techniques:
- Ribosome Density Fractionation: Sucrose gradient centrifugation to separate mRNAs based on ribosome binding (monosomes vs. polysomes) to assess translational activity.
- Immunoblotting & qRT-PCR: To quantify viral protein levels (Immediate Early, Early, Late) and mRNA abundance.
- TCID50 Assay: To measure infectious virion production in HEK-AD293 cells.
- RNA-Sequencing (Bulk-RNAseq): To analyze the global host transcriptome in eIF5B-depleted KSHV-infected cells.
- Functional Assays: IncuCyte live-cell imaging for proliferation, ELISA for VEGF secretion, and soft-agar assays for anchorage-independent growth (oncogenicity).
- Immunohistochemistry (IHC): Staining of human AIDS-KS tumor biopsies (early to nodular stages) for KSHV LANA and eIF5B.

3. Key Contributions & Results

A. KSHV Induces eIF2 Inhibition and Upregulates eIF5B

During lytic reactivation, KSHV infection leads to significant phosphorylation of eIF2 $\alpha$ (inhibiting the canonical initiation factor eIF2).
Concurrently, KSHV infection causes a marked upregulation of eIF5B (both mRNA and protein) specifically during the late lytic stage (48–72 hours post-induction).
Unlike eIF5B, other translation factors (eIF4E1, eIF4G1, eIF4A, eIF4G3, RBM4) did not show comparable upregulation; some were even downregulated.

B. eIF5B is Essential for Late Lytic Replication

Selective Translation: Silencing eIF5B in iSLK.219 cells had no effect on Immediate Early (IE) or Early (E) viral proteins (RTA, ORF45, ORF57) but caused a near-complete ablation of Late (L) lytic proteins (gB, K8.1).
Virion Production: eIF5B knockdown reduced infectious virion production by ~74% at 48 hours and ~46% at 72 hours.
Ribosome Association: Ribosome profiling revealed that during KSHV infection, eIF2 accumulates in translationally inactive monosome fractions, while eIF5B redistributes to active polysome fractions, indicating it is actively driving translation.
Specificity: Silencing eIF2D (another alternative factor) did not replicate the effects of eIF5B depletion, confirming the specific reliance on eIF5B.

C. eIF5B Creates a Hypoxia-Like Transcriptomic Landscape

Transcriptomic Mimicry: RNA-seq analysis of eIF5B-depleted KSHV-infected cells showed a gene expression profile that closely mirrored uninfected cells under hypoxic stress.
Pathway Enrichment: Depletion of eIF5B in infected cells led to the downregulation of pathways associated with hypoxia, glycolysis (Warburg effect), and epithelial-to-mesenchymal transition (EMT).
Mechanism: This suggests that KSHV utilizes eIF5B not just for viral protein synthesis, but to actively reprogram the host cell into a hypoxic-like state that favors viral replication and oncogenesis.

D. Role in Oncogenesis and Natural Infection Models

Infectivity: In primary hMSCs (a natural reservoir), eIF5B knockdown reduced de novo infection rates by 50% and blocked virion production.
Oncogenic Markers: In KS-like media, eIF5B depletion significantly reduced:
- Secretion of VEGF (a key angiogenic factor).
- Anchorage-independent growth (soft-agar colony formation) in mouse MSCs.
Clinical Relevance: IHC analysis of human AIDS-KS lesions showed robust eIF5B staining in nodular (advanced) tumors. Interestingly, eIF5B-positive cells were spatially enriched in infected regions, though the number of eIF5B-positive cells decreased within LANA-positive (infected) areas compared to uninfected areas in nodular tumors, suggesting a complex dynamic in late-stage tumorigenesis.

4. Significance

Novel Viral Strategy: The study identifies a previously unrecognized viral strategy where KSHV co-opts an archaic, evolutionarily conserved translation factor (eIF5B)—typically used only under severe hypoxia—to bypass host translational shutoff mechanisms during normoxic infection.
Mechanistic Insight: It elucidates the molecular basis of "Translation Initiation Plasticity" (TRIP) in KSHV, demonstrating a switch from eIF2-dependency to eIF5B-dependency to sustain late lytic gene expression.
Oncogenic Link: The research connects viral replication machinery directly to cellular transformation. By forcing the host cell to utilize eIF5B, KSHV mimics a hypoxic environment, driving glycolytic shifts and EMT, which are hallmarks of cancer.
Therapeutic Potential: eIF5B is highlighted as a potential therapeutic target. Since eIF5B is dispensable for normal cell growth under normoxia but critical for KSHV replication and oncogenesis, inhibiting it could selectively block viral pathogenesis and tumor growth without severe toxicity to the host. This is particularly relevant given eIF5B's role in other cancers (e.g., lung adenocarcinoma) and its ability to translate PD-L1.

In summary, this paper demonstrates that KSHV hijacks the ancient eIF5B machinery to create a hypoxia-like niche, enabling efficient viral replication and driving the cellular changes necessary for oncogenesis, thereby offering a new avenue for targeted antiviral and anti-cancer therapies.